The shadow of generic rivalry has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of related pharmaceutical investments. While initial times saw substantial gains, the exclusivity expiration has allowed the path for discounted alter